What a genuinely complex situation — and your concern about whether your medical teams are truly coordinating with each other is not only valid, it's one of the most important questions you can be asking right now.
With MP-CMML-1 and a high CPSS-Mol genetic risk score, plus mutations in ASXL1, RUNX1, and SRSF2, your Show Full Answer
What a genuinely complex situation — and your concern about whether your medical teams are truly coordinating with each other is not only valid, it's one of the most important questions you can be asking right now.
With MP-CMML-1 and a high CPSS-Mol genetic risk score, plus mutations in ASXL1, RUNX1, and SRSF2, your leukemia profile alone is serious. The proliferative subtype (MP-CMML) means your white blood cell counts are elevated, which brings its own set of complications. Your concern about siloed medical care is well-founded. Here's why coordinated care matters so much in your specific situation:
- Tacrolimus (your anti-rejection medication) suppresses your immune system, which directly impacts how your body handles leukemia and any potential CMML treatments
- MP-CMML itself causes high white blood cell counts, which interacts with an already immunocompromised state
- Your high-risk genetic mutations (especially ASXL1 and RUNX1) are associated with a less favorable outlook and may eventually require more aggressive treatment decisions
- A "wait and see" approach is common early on, but with a high-risk score, timelines for reassessment matter The most important step you can take right now is to strongly advocate for a multidisciplinary team (MDT) meeting — where your oncologist, transplant hepatologist, cardiologist, and nephrologist are all in the same conversation, not just their own lanes.
Ask your oncologist directly: *"Are you in communication with my transplant team about how CMML treatment options might interact with my immunosuppression?"* It's also worth asking about clinical trials specifically designed for high-risk CMML, as treatment options are actively evolving. Given your transplant history, not all standard CMML treatments may be appropriate — which makes a coordinated specialist review even more critical.
A MyLeukemiaTeam member in a similarly complex situation once noted that pushing for a second opinion at a major cancer center that specializes in CMML made a significant difference in how their care was coordinated.
4 days ago
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
